UCD Conway Focus Spring 2014

Page 1

/ 0 " 3

Issue 21,23 3 Spring 2014

4

" Prestigious awards to Conway Researchers 1 ! The Sir Henry Wellcome postdoctoral % scheme aims to fellowship provide the

promising 5 6

most newly qualified researchers with a postdoctoral unique (67 -! ! opportunity to develop independent research ! careers. For8 ! the first time, the 5 this Wellcome Trust has awarded $

fellowship to an ' Irish early career !

7 researcher, Dr Colm Ryan.

1

9 4

: (9 4 :- Dr Ryan will work with Prof Walter Kolch, % ! 5 Systems Biology Ireland and Prof Alan 6

$

Ashworth, Institute of Cancer Research,

London to investigate how genetic changes impact on a targeted approach to cancer ! " treatment.

# $

in " % A major challenge cancer therapeutics is & " other to kill tumour cells without harming $

have

cells in the body. Cancer cells genetic that " % changes distinguish them from healthy

cells, and consequently may leave them ' (" ) "

vulnerable treatments. to targeted *+ , - A promising approach to $ developing .

" such targeted " treatments to identify

" " % is. genes

" whose function is only essential for survival cancer-associ in the presence of a specific % ated mutation. Such a phenomenon, where the function of gene A becomes essential

/" # only in the presence of a mutation in gene " -+ B, is called synthetic lethality. However, + % " little is understood about how additional +% "

genetic differences between individuals might impact on their use.

" lethality " impact on synthetic treatments,

" treat and investigating whether certain be more

genetic ments might robust to differences than others. " %

The 11th Luke’s Young . St " " Investigator " award was won by Irish Cancer Society research fellow, Dr Maria Prencipe at the Royal "

College Physicians of Ireland on January

% . of 29th 2014. *01., % ' " This prestigious award supported the

by Royal Academy of Medicine in Ireland and " St " Luke’s Radiation Oncology

Network, " work to Dublin went to Dr Prencipe for her " 01.% for castration find a new molecular target resistant prostate cancer (CRPC).

- 23 " " Dr Maria Prencipe colleagues and working with Fellow, Prof William Watson Conway " " recently identified the transcription factor $% 4 " named serum response factor as an (SRF) " important target in CRPC using and " genetic computational analyses. " "

%

$ "

head-on, clinicians and scientists need to mechanisms

% understand the underlying of resistance.

' (" " “Our study shows evidence of cross-talk "

" between receptor (AR) androgen " and SRF in advanced prostate cancer. At the core of / 5 " ' ' this cross-talk is a negative loop feedback between SRF and AR that were able to we

" demonstrate in vitro, clinical samples and " " in is % supported by a computational model�,

said Dr Prencipe. Prof Walter Kolch, Director & 6. both Maria

on said, “I congratulate Colm and (" " their achievements. It is fitting " " ! " recognition for their dedication to fundamental cancer research and " improving outcomes for patients with 5 " %7 advanced disease�. " " 8 + % + & 9 : 0 : : . . 1 1 + + : . : : ' (" ;% + ' % 23 3 / 22< ==*>,?@A >@

When prostate cancer is detected early in

0 "

patients, surgery and radiation

" " " " treatments are effective therapies. Patients $ " with locally advanced and metastatic prostate cancer are treated with androgen

ablation (hormone depletion or chemical " " castration) therapy. "

Despite an initial response, the majority of men progress to develop castration-resistant prostate cancer which, despite the emergence of new treatments, is challenging to treat. To meet this challenge

Dr Maria Prencipe

) /

Dr Ryan’s fellowship will focus on understanding how such genetic changes

Director’s Message

1

8 8

;

Welcome!

" " facilities In the last quarter, the dedicated for Systems Biology Ireland adjacent $ to Conway Institute became UCD " (" operational; new director of UCD " the

$ Charles Institute of Dermatology, Prof

% . Martin Steinhoff joined UCD from " B ' University of California San Francisco; and ' =3 the Institute hosted the first UCD Ireland ;- 23 ;- " A East cancer open house. " %

4 " C " < The UCD Ireland East cancer open house / " provided a unique opportunity for cancer " " " " survivors, patient advocacy groups and

clinicians from across the Ireland East " " network to sit at the laboratory bench and %

talk with researchers about the projects they are working on in the battle against 4 cancer. The dedication and passion of our

was -+ evident early career researchers clearly $

and, in turn, they were inspired by the " who individuals might ultimately benefit " " from this research.

Dr Colm Ryan " / 0 23 3%

0 developments " many These create " " and integrative interfaces for collaboration undoubtedly " strengthen impact and will the Institute’s priority of strategic

" + building a strong translational medicine programme. " "

Professor Walter Kolch "

% Director

B 4 : -+ + 0 "

<2:4 <7' ' ' 1 '0 / D;+-D E '0 /; 0+ D ; ; +&


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
UCD Conway Focus Spring 2014 by UCD Conway Institute - Issuu